Format

Send to

Choose Destination
J Neuroimmunol. 2012 Feb 29;243(1-2):43-51. doi: 10.1016/j.jneuroim.2011.12.018. Epub 2012 Jan 20.

Rapamycin reduces clinical signs and neuropathic pain in a chronic model of experimental autoimmune encephalomyelitis.

Author information

1
Institute of Pharmacology, Catholic University Medical School, Rome, Italy.

Abstract

Current treatments used in Multiple Sclerosis (MS) are partly effective in the early stages of the disease but display very limited benefits in patients affected by progressive MS. One possible explanation is that these therapies are unable to target the inflammatory component most active during the progressive phase of the disease, and compartmentalized behind the blood-brain barrier. Our findings show that Rapamycin ameliorates clinical and histological signs of chronic EAE when administered during ongoing disease. Moreover, Rapamycin significantly reduced the hyperalgesia observed before clinical development of EAE which, in turn, is completely abolished by the administration of the drug.

PMID:
22264993
DOI:
10.1016/j.jneuroim.2011.12.018
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center